Background: Transient tachypnea of the newborn (TTN) is a common cause of respiratory distress in the neonatal period. There are few data regarding the pharmacotherapy for the management of TTN. Previous studies documented the therapeutic role for the beta2 agonists in TTN by accelerating the clearance of excessive fluid from the alveolar space. The aim of present study was to assess the effect of salbutamol on major clinical course including duration of oxygen therapy and improvement of respiratory symptoms.
Objectives: to evaluate the efficacy of inhaled salbutamol, a beta-2 adrenergic agonist, for the treatment of transient tachypnea of the newborn and to determine whether inhaled salbutamol is safe in newborn infants born between 36th and 39th weeks.
Methods: It is randomized controlled clinical trial, on 100 neonates who was admitted immediately or shortly after birth due to persistence of tachypnea to neonatal intensive care unit (NICU) of Al Hussein and Bab al sharia university hospitals. (50 on salbutamol therapy(group A), 50 As control (group B) with RD born between 36th and 39th weeks of gestational age infants will be randomized in a blinded manner to receive one nebulized dose of salbutamol 0.15 mg/kg in 0.9% saline solution in addition to oxygen and IV fluids (group A) or received only oxygen and IV fluids (group B) .The response to inhaled salbutamol will be evaluated by determining respiratory rate, heart rate, clinical score of transient tachypnea of the newborn, level of respiratory support, before and at 30 minutes and 1 and 4 hours after drugs therapy.
Results: There is significant decrease in respiratory rate and TTN score in (group A) 4 hours after nebulized salbutamol.
Conclusion: Inhaled salbutamol treatment was effective in TTN without adverse events.